CME-accredited
Webinar:

The Use of Angiotensin II in Vasodilatory Shock

Join our panel of experts in the field of intensive care for this CME-accredited webinar covering vasodilatory shock, the current vasoactive agents, and a critical evaluation of emerging therapies including angiotensin II.

This educational activity is free of charge.

Launch course

Learning Objectives:

The goal of this activity is to better equip learners to evaluate and manage patients with vasodilatory shock through detailed discussions on the emerging treatment options.

  • Describe vasodilatory shock from a pathophysiologic standpoint.
  • Identify the relevant risk factors and clinical features associated with increased morbidity and mortality associated with vasodilatory shock.
  • Explain the mechanism of action, pharmacologic properties, and safety and efficacy of current vasoactive agents, particularly angiotensin II, for the treatment of vasodilatory shock.
  • Identify and critique the application of emerging therapies, including the use of angiotensin II, for the treatment of vasodilatory shock.

Faculty

Ashish Kumar Khanna, MD

Ashish Kumar Khanna, MD

Associate Professor of Anesthesiology and Vice-Chair of Research, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Giovanni Landoni, MD

Giovanni Landoni, MD

Full Professor, Vita-Salute San Raffaele University, Milan, and Director of the Center for Intensive Care and Anesthesiology of San Raffaele Scientific Institute, Italy

Ben Creagh-Brown, MD

Ben Creagh-Brown, MD

Consultant of Critical Care Medicine, Royal Surrey Hospital, and Honorary Reader, University of Surrey, UK

learning_resources

Length of Education: 60 minutes

Release date: September 2023

Financial disclosures:

Ashish Kumar Khanna
Research: La Jolla Pharmaceuticals
Promotional activities (Consultant): La Jolla Pharmaceuticals

Giovanni Landoni
Honoraria for educational activities: Medis, Mylan (Viatris), Paion

Ben Creagh-Brown does not have any relevant financial relationships to disclose.

CME Information:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) through the joint providership of Siyemi Learning and EMJ.

Siyemi Learning is an EBAC accredited provider since 2023. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.

Siyemi Learning designates this activity for 1 EBAC CE Credit(s).

EBAC CME Logo

How to earn your CME credit

In order to obtain your CME credit and acquire your certificate, please launch the course to watch the webinar before completing the multiple-choice assessment.

The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and the American Medical Association (AMA), physicians may convert EBAC CE credits to AMA PRA Category 1 CreditsTM. Information on the process can be found on the AMA website (https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-board-accreditation-continuing-education-health)

Any queries, please email: cme@emjreviews.com

Commercial support:

This CME activity is funded by an educational grant from Viatris.

button